User login
Key clinical point: Primary tumor location (PTL) is not a significant prognostic factor in patients with metastatic colorectal cancer (mCRC) under later-line regorafenib (REG) or trifluridine/tipiracil (FTD/TPI).
Major finding: Although overall survival (OS) was significantly shorter in patients with right-sided vsvs left-sided tumors (log-rank P = .041), PTL was not an independent prognostic factor (adjusted hazard ratio, 0.95; P = .64). OS was comparable between REG and FTD/TPI in both right-sided (log-rank P = 0.71) and left-sided (log-rank P = 0.56) tumor groups regardless of PTL (P for interactions = 0.60).
Study details: Findings are from a retrospective study of 550 patients with mCRC from the REGOTAS study treated with later-line REG (n=223) or FTD/TPI (n=327) chemotherapy. Right-sided tumors were reported in 60 and 62 patients in REG and FTD/TPI groups, respectively.
Disclosures: The authors did not declare any source of funding. Some of the authors reported receiving research funding and/or honoraria from various sources.
Source: Nakajima H et al. Front Oncol. 2021 Jun 15. doi: 10.3389/fonc.2021.688709.
Key clinical point: Primary tumor location (PTL) is not a significant prognostic factor in patients with metastatic colorectal cancer (mCRC) under later-line regorafenib (REG) or trifluridine/tipiracil (FTD/TPI).
Major finding: Although overall survival (OS) was significantly shorter in patients with right-sided vsvs left-sided tumors (log-rank P = .041), PTL was not an independent prognostic factor (adjusted hazard ratio, 0.95; P = .64). OS was comparable between REG and FTD/TPI in both right-sided (log-rank P = 0.71) and left-sided (log-rank P = 0.56) tumor groups regardless of PTL (P for interactions = 0.60).
Study details: Findings are from a retrospective study of 550 patients with mCRC from the REGOTAS study treated with later-line REG (n=223) or FTD/TPI (n=327) chemotherapy. Right-sided tumors were reported in 60 and 62 patients in REG and FTD/TPI groups, respectively.
Disclosures: The authors did not declare any source of funding. Some of the authors reported receiving research funding and/or honoraria from various sources.
Source: Nakajima H et al. Front Oncol. 2021 Jun 15. doi: 10.3389/fonc.2021.688709.
Key clinical point: Primary tumor location (PTL) is not a significant prognostic factor in patients with metastatic colorectal cancer (mCRC) under later-line regorafenib (REG) or trifluridine/tipiracil (FTD/TPI).
Major finding: Although overall survival (OS) was significantly shorter in patients with right-sided vsvs left-sided tumors (log-rank P = .041), PTL was not an independent prognostic factor (adjusted hazard ratio, 0.95; P = .64). OS was comparable between REG and FTD/TPI in both right-sided (log-rank P = 0.71) and left-sided (log-rank P = 0.56) tumor groups regardless of PTL (P for interactions = 0.60).
Study details: Findings are from a retrospective study of 550 patients with mCRC from the REGOTAS study treated with later-line REG (n=223) or FTD/TPI (n=327) chemotherapy. Right-sided tumors were reported in 60 and 62 patients in REG and FTD/TPI groups, respectively.
Disclosures: The authors did not declare any source of funding. Some of the authors reported receiving research funding and/or honoraria from various sources.
Source: Nakajima H et al. Front Oncol. 2021 Jun 15. doi: 10.3389/fonc.2021.688709.